Halozyme Therapeutics Inc (NAS:HALO)
$ 61.42 0.44 (0.72%) Market Cap: 7.81 Bil Enterprise Value: 8.65 Bil PE Ratio: 20.34 PB Ratio: 17.25 GF Score: 90/100

Halozyme Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 04:30PM GMT
Release Date Price: $42.68 (-7.42%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Thanks, operator, and good day, everybody. My name is Jason Gerberry, mid-cap Biotech Analyst at Bank of America, and I am pleased to be introducing our next company presenter at the Bank of America Annual Healthcare Conference, joined by Halozyme Therapeutics, and CEO, Helen Torley. Helen, thanks so much for joining us. Helen's got a prepared presentation. So I'm going to turn it over to her.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Thank you, Jason, and thanks, everyone, for joining us today. It's really a pleasure to be here to provide an update on Halozyme's strategy and our progress on mission's accomplishments. I'll begin on Slide 2 and just to mention of the forward-looking statements. In the course of the presentation, I will be making forward-looking statements, and I refer you to our SEC filings for full listing of the risks and uncertainties.

Next slide. Let me begin with a summary of our business. We are the sole owners

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot